• The New Money
  • Posts
  • America's First GLP-1 Pill, 3D Printing For The DoW, And Starfighters Debuts On The NYSE

America's First GLP-1 Pill, 3D Printing For The DoW, And Starfighters Debuts On The NYSE

The markets and trends that matter, made simple. Discover what’s next.

December 23, 2025

The First Ever GLP-1 Pill Is Coming To The USA

Novo Nordisk (NYSE: NVO) has been granted regulatory approval from the United States Food and Drug Administration for their Wegovy GLP-1 pill for weight loss, marking the first approval in U.S. history for an oral GLP-1 pill. The Wegovy pill uses the same active ingredients as the injectable versions of both Wegovy and Ozempic and is only required to be taken once per day.

Velo3D Wins Department of War Manufacturing Deal

Velo3D (NASDAQ: VELO) won a $32.6 million contract from the United States Department of War to use advanced additive manufacturing to accelerate a large scale munitions weapon system program. Velo3D will closely collaborate with the Department of War’s Innovation Unit and the United States Navy to determine which parts and materials could be meaningfully scaled up through 3D printing and advanced additive manufacturing.

Starfighters Space Makes NYSE Debut

Starfighters Space (NYSE: FJET) officially completed their $40 million Regulation A initial public offering and began trading on the New York Stock Exchange. Starfighters Space is one of the first publicly traded companies focused on using piloted supersonic jets for small satellite air launches and hypersonic test missions. Their commercial fleet of F-104 supersonic aircraft are capable of Mach 2 operations and payload deployment at extremely high altitudes.

Discover the world’s most exciting stocks, easier than ever before. Download The New Money App.

The Sprint

Looking to connect? Reach out and get in touch.

New here? Join our community of 100,000+ individuals interested in uncovering the world’s most exciting early stage companies.

Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.